When was Scribe Therapeutics founded?

Scribe Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Scribe Therapeutics located?

Scribe Therapeutics is headquartered in Alameda, United States.

Who is the current CEO of Scribe Therapeutics?

Benjamin L Oakes of Scribe Therapeutics. They have also founded 1 company.

How many employees does Scribe Therapeutics have?

As of May 31, 2026, the latest employee count at Scribe Therapeutics is 88.

Is Scribe Therapeutics a funded company?

Scribe Therapeutics is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 06, 2020.

When was the latest funding round of Scribe Therapeutics?

Scribe Therapeutics' latest funding was a $***** Grant (prize money) round on Jun 18, 2026, with participation from 1 investor.

Where does Scribe Therapeutics rank among its competitors?

Scribe Therapeutics ranks 8th amongst 116 active competitors, of which 59 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Kytopen, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of Scribe Therapeutics?

Scribe Therapeutics' top competitors include Beam Therapeutics, eGenesis and Mammoth. Among them, Scribe Therapeutics secured the most recent funding round in June, 2026.

Scribe Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a gene-editing platform using CRISPR technology. CRISPR technology is used to knock out/in the targeted gene from the DNA. The company's proprietary CRISPR-based X-editing (XE) technology is used for in vivo modification of genes. This technology uses CasX enzymes that comprise a specific family of guide RNA to edit the genome. The company aims to use XE technology to treat several genetic diseases including neurological diseases, ophthalmological diseases, hematopoietic disorders, and also in cell therapy.

Website: www.scribetx.com/
Social
Email ID: *****@scribetx.com

Key Metrics

Founded Year

2018

Location

Alameda, United States

Stage

Series B

Total Funding

$120M in 3 rounds

Latest Funding Round

Grant (prize money), Jun 18, 2026, $*****

Investors

Andreessen Horowitz & 7 more

Ranked

8^th among 116 active competitors

Employee Count

88 as on May 31, 2026

Similar Companies

Beam Therapeutics & 131 more

View Scribe Therapeutics' full profile

Scribe Therapeutics has raised a total funding of $120M over 3 rounds. Its first funding round was on Oct 06, 2020. Its latest funding round was a Grant (prize money) round on Jun 18, 2026 for $*****. 1 investor participated in its latest round. Scribe Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Scribe Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 18, 2026	9947845	Grant (prize money)	9471980	6394521	4016094	1849181
Mar 17, 2021	1620118	Series B	5731636	2884859	7581892	Orbimed & 6 more
Oct 06, 2020	2713798	Series A	8764294	7624900	Andreessen Horowitz	6075891

Access funding benchmarks and valuations. Sign up today!

View details of Scribe Therapeutics's funding rounds and investors

The founders of Scribe Therapeutics are Benjamin L Oakes, Jennifer A Doudna, Brett Staahl and David F Savage.

Here are the details of Scribe Therapeutics' key team members:

Benjamin L Oakes: Co-Founder & CEO & President of Scribe Therapeutics and founder of 1 other company.
Contact Info: 1 email address
Jennifer A Doudna: Co-Founder & Scientific Advisor of Scribe Therapeutics.
Brett Staahl: Co-Founder and VP Platform, Scribe Therapeutics Inc. of Scribe Therapeutics.
David F Savage: Co-Founder & Scientific Advisor of Scribe Therapeutics.
Contact Info: 1 email address

View details of Scribe Therapeutics's Founder profiles and Board Members

Scribe Therapeutics' employee count trend

Scribe Therapeutics has 88 employees as of May 26. Here is Scribe Therapeutics's employee count trend over the years:

Employee count trend for Scribe Therapeutics

Uncover Scribe Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Scribe Therapeutics include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of Scribe Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Google Ventures, F-Prime Capital & 16 others	71/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	HBM Healthcare Investments, Lux Capital & 30 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, 8VC & 34 others	65/100
4th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
5th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	Temasek, SoftBank Vision Fund & 22 others	64/100
6th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Tencent, Illumina & 13 others	64/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	PSP Investments, Google Ventures & 10 others	64/100
8th	Scribe Therapeutics 2018, Alameda (United States), Series B	Developer of a gene-editing platform using CRISPR technology	$120M	Wellington, RA Capital Management & 6 others	62/100
9th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Engine Ventures, Telegraph Hill Partners ... & 11 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Eclipse, Decheng Capital	60/100